Trimetazidine, Administered at the Onset of Reperfusion, Ameliorates Myocardial Dysfunction and Injury by Activation of p38 Mitogen-Activated Protein Kinase and Akt Signaling

Trimetazidine [1-(2,3,4-trimethoxybenzyl)piperazine; TMZ] is an anti-ischemic cardiac drug; however, its efficacy and mechanism of cardioprotection upon reperfusion are largely unknown. The objective of this study was to determine whether TMZ, given before reperfusion, could attenuate myocardial rep...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Khan, Mahmood, Meduru, Sarath, Mostafa, Mahmoud, Khan, Saniya, Hideg, Kàlmàn, Kuppusamy, Periannan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The American Society for Pharmacology and Experimental Therapeutics 2010
Gaiak:
Cardiovascular
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2872960/
https://ncbi.nlm.nih.gov/pubmed/20167841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.109.165175
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak